Autor(es): Xin Ning; Namaka Michael Peter; Dou Changxin; Zhang Yong

Resumo: Interleukin-22 (IL-22) is a member of the IL-10 cytokine family that has recently gained attention in regard to its recognized pathogenic role in neurological and autoimmune disorders. The pathological involvement of IL-22 has been linked to Th17 cells that are involved in its production. Its biological activity results from its ability to bind to a heterodimeric receptor consisting of IL-22 receptor 1 (IL-22R1) and IL-10R2. Emerging evidence has identified IL-22 involvement in neurological diseases and autoimmune disorders such as Guillain-Barré Syndrome (GBS), multiple sclerosis (MS), Alzheimer's disease (AD), encephalitis, inflammatory myopathies, myasthenia gravis (MG), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjogren's syndrome (SS), psoriasis and Crohn's disease (CD). However, the biological activity of IL-22 is variable resulting in protective or pathogenic effects in different disease states. As such, the development of therapeutic targeting strategies to modify the biological activity of IL-22 is being explored as a promising interventional approach to treat neurological and autoimmune diseases.

Palavras-Chave: Autoimmune diseases, Cytokines, IL-22, Interventional therapeutics, Neurological diseases, Th17

Imprenta: International Immunopharmacology, v. 28, n. 2, p. 1076-1083, 2015

Identificador do objeto digital: 10.1016/j.intimp.2015.08.016

Descritores: Guillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Cytokines

Data de publicação: 2015

Indicadores

ACESSO